JP2018522812A - カスパーゼ−６のモジュレーター - Google Patents

カスパーゼ−６のモジュレーター Download PDF

Info

Publication number
JP2018522812A
JP2018522812A JP2016552512A JP2016552512A JP2018522812A JP 2018522812 A JP2018522812 A JP 2018522812A JP 2016552512 A JP2016552512 A JP 2016552512A JP 2016552512 A JP2016552512 A JP 2016552512A JP 2018522812 A JP2018522812 A JP 2018522812A
Authority
JP
Japan
Prior art keywords
nervous system
caspase
pharmaceutical composition
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016552512A
Other languages
English (en)
Japanese (ja)
Inventor
メディ マイク カーンキシュプール，
メディ マイク カーンキシュプール，
オルガ ペティーナ，
オルガ ペティーナ，
デートレフ ゲフケン，
デートレフ ゲフケン，
ダグマー エルンホファー，
ダグマー エルンホファー，
マイケル ヘイデン，
マイケル ヘイデン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Hamburg
Original Assignee
Universitaet Hamburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Hamburg filed Critical Universitaet Hamburg
Publication of JP2018522812A publication Critical patent/JP2018522812A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/28—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016552512A 2014-08-05 2015-02-14 カスパーゼ−６のモジュレーター Pending JP2018522812A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033401P 2014-08-05 2014-08-05
US62/033,401 2014-08-05
PCT/IB2015/000144 WO2016020732A1 (fr) 2014-08-05 2015-02-14 Modulateurs de caspase 6

Publications (1)

Publication Number Publication Date
JP2018522812A true JP2018522812A (ja) 2018-08-16

Family

ID=55263221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016552512A Pending JP2018522812A (ja) 2014-08-05 2015-02-14 カスパーゼ−６のモジュレーター

Country Status (6)

Country Link
EP (1) EP3129027A4 (fr)
JP (1) JP2018522812A (fr)
AU (1) AU2015298491A1 (fr)
CA (1) CA2939655A1 (fr)
DE (1) DE112015001269T5 (fr)
WO (1) WO2016020732A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265445B1 (fr) 2015-03-06 2021-05-05 Pharmakea, Inc. Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs
AU2016229268B2 (en) 2015-03-06 2020-09-10 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
CA3013917A1 (fr) 2016-02-09 2017-08-17 Pharmakea, Inc. Inhibiteurs quinolinone de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs
CA3036064A1 (fr) 2016-09-07 2018-03-15 Pharmakea, Inc. Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procedes de fabrication
WO2018048942A1 (fr) 2016-09-07 2018-03-15 Pharmakea, Inc. Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase
BR112022009881A2 (pt) * 2019-11-22 2022-10-11 Univ California Inibidores de caspase 6 e usos dos mesmos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0818439B1 (fr) * 1996-07-02 1999-10-13 Nisshin Flour Milling Co., Ltd. Dérivés d'imides
EP2102189B1 (fr) * 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Analogues d'arylpropionamide, d'arylacrylamide, d'arylpropynamide ou d'arylméthylurée en tant qu'inhibiteurs du facteur xia
WO2010017408A1 (fr) * 2008-08-06 2010-02-11 The Buck Institute For Age Research Inhibiteurs de caspase, et leurs utilisations

Also Published As

Publication number Publication date
WO2016020732A1 (fr) 2016-02-11
DE112015001269T5 (de) 2017-06-08
CA2939655A1 (fr) 2016-02-11
AU2015298491A1 (en) 2016-09-01
EP3129027A1 (fr) 2017-02-15
EP3129027A4 (fr) 2017-06-21

Similar Documents

Publication Publication Date Title
JP2018522812A (ja) カスパーゼ−６のモジュレーター
US10357508B2 (en) APP specific BACE inhibitors (ASBIs) and uses thereof
US11083798B2 (en) Conjugate including peptide molecule capable of self-assembly in cell organelle and pharmaceutical composition for preventing or treating cancer including conjugate
JP6877424B2 (ja) アルギニンジンジパインの阻害剤
US20070213388A1 (en) Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Antagonists Useful in the Treatment of of Cognitive Disorders
JP6595345B2 (ja) コンフォメーション病におけるβタンパク質凝集の新規の分子モジュレーターとしての化学シャペロニン
EA006021B1 (ru) Применение липосом для транспорта лекарственных средств или веществ с косметической активностью на основе сложных эфиров l-карнитина и композиции, включающие липосомы
CN116867488A (zh) 用于治疗干性老年性黄斑变性（amd）的组合物
WO2013123426A1 (fr) Formulations et procédés destinés au traitement ou à la prophylaxie d'états de pré-mci et/ou de pré-alzheimer
US20190192524A1 (en) Modulators of Caspase-6
WO2023062451A1 (fr) Tat-efsevine-ta pegylée en tant qu'agent antiarythmie ayant un effet favorable sur l'insuffisance cardiaque provoquée par l'arythmie
JP2015521636A (ja) ｉｎ−ｖｉｖｏで神経変性疾患（特にアルツハイマー病）に活性なリポソーム
JP2016533317A (ja) 多発性嚢胞腎の予防及び／又は治療薬
JP6688503B2 (ja) 医薬用組成物
CA3028629A1 (fr) Derive d'oxazine pour utilisation dans la prevention de la maladie d'alzheimer chez des patients a risque
HUE034353T2 (en) Preparation containing a benzothiazolone compound
WO2017222042A1 (fr) Composition pharmaceutique ophtalmique
KR20230159546A (ko) 신경학적 질환을 치료하기 위한 조성물 및 방법
Gado et al. Physicochemical properties for potential Alzheimer’s disease drugs
JP2007518786A (ja) アミロイドーシスを治療するためのアミジン誘導体
US12589090B2 (en) Compounds and methods for the treatment of degenerative disorders
Huo et al. Current Research on Pro-drug Therapies for Parkinson's and Alzheimer's Disease
US20240174718A1 (en) Ryanodine receptor inhibitor compounds and methods relating thereto
US20110136774A1 (en) Anti-Apoptotic Benzodiazepine Receptor Ligand Inhibitors
WO2026002967A1 (fr) Léoligine et ses dérivés en tant que bloqueurs des canaux calciques pour la prévention et/ou le traitement de maladies associées